Download PDF
Physikalische Medizin, Rehabilitationsmedizin, Kurortmedizin 2017; 27(03): 171-178
DOI: 10.1055/s-0043-110606
Fort- und Weiterbildung
© Georg Thieme Verlag KG Stuttgart · New York

Wirkung und Nebenwirkungen von Ibuprofen

Mechanism of Action and Side Effects of Ibuprofen
Florentine Jahn
1   Zentrum für Zahn-, Mund- und Kieferheilkunde, Universitätsklinikum Jena, Jena
› Author Affiliations
Further Information

Publication History

Publication Date:
28 June 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Ibuprofen ist ein weit verbreitetes nichtsteroidales Antiphlogistikum (NSAID). Es hemmt durch Blockade des aktiven Zentrums die Cyclooxygenase 1 und 2 (COX-1 und COX-2) reversibel. In höheren Konzentrationen als die zur Hemmung der COX-1 und COX-2 notwendig sind, zeigt es Antitumor-Aktivität. In OTC-Dosierung (over the counter) (<1200 mg/d) ist das Risiko zur Entstehung von gastrointestinalen Blutungen geringer als bei Diclofenac, Naproxen, Piroxicam oder Indomethacin. Mit Erhöhung der Dosis (2400–3200 mg/d) und Verlängerung der Therapiedauer steigt das Risiko für gastrointestinale Nebenwirkungen. Bei höheren Dosierungen und schon eingeschränkter Nierenfunktion kann Ibuprofen zu einem akuten Nierenversagen führen. Eine Kontrolle der Nierenfunktion ist in diesen Fällen angezeigt. Bei Kindern bis zu 12 Jahren, bei Schwangeren und auch älteren Patienten sollte Paracetamol der Vorzug gegeben werden. Patienten mit Hypertonie, welche mit ACE-Hemmern, Angiotensin-II-Rezeptorenblockern oder Thiazid-Diuretika behandelt werden, sollten Ibuprofen nicht über einen längeren Zeitraum einnehmen. Bei gleichzeitiger Einnahme von Ibuprofen und Acetylsalicylsäure wird die irreversible Hemmung von ASS auf die COX-1 vermindert, da Ibuprofen eine höhere Affinität zum aktiven Zentrum der COX-1 besitzt.

Eine kurzzeitige Behandlung mit Ibuprofen ist meist unproblematisch. Bei längerfristiger Therapie und höherer Dosierung muss zwischen niedrigem und hohem gastrointestinalem und kardiovaskulärem Risiko differenziert werden.

Abstract

Ibuprofen is a commonly used non-steroidal anti-inflammatory drug (NSAID). It inhibits the active center of cyclooxygenase 1 and 2 (COX-1 and COX-2) reversibly. In a concentration higher than for the inhibition of COX-1 and COX-2, ibuprofen inhibits tumorigenesis. In the ”over the counter dosage (<1200 mg/d)”, the risk for gastrointestinal bleeding is lower than for diclofenac, naproxen, piroxicam or indomethacin. However, with increasing dosage (2400–3200 mg/d) over a longer period of time, more gastrointestinal complications can occur. It is possible to induce an acute renal failure in patients with a limited renal function. In these cases, an observation of the renal function is recommended. For children up to an age of 12 years, pregnant women and elderly patients the NSAID of choice should be paracetamol. In combination with ACEIs (angiotensinogen converting enzyme inhibitors), ARBs (angiotensin receptor blockers) and thiazide diuretics, medication that is commonly used for the treatment of hypertension, chronic use of ibuprofen should be avoided. A simultaneous intake of ibuprofen and acetylsalicylic acid can reduce the irreversible inhibition of COX-1 by acetylsalicylic acid since ibuprofen has a higher affinity to the active center of COX-1.

Taken together, a short time ibuprofen treatment usually does not cause any problems. A therapy with ibuprofen over a longer period of time and in a higher dosage should be considered a high gastrointestinal or cardiovascular risk for the patient.

Schlüsselwörter

Ibuprofen - Wirkmechansimus - OTC-Dosierung - UAW des Ibuprofen - Interaktionen - Gastrointestinales Risiko - Cardivaskuläres Risiko

Key words

ibuprofen - mechanism of action - OTC-dosage - side effects - interactions - gastrointestinal risk - cardiovascular risk
 

  • Literatur

  • 1 Lüllmann H, Mohr K, Hein L. Pharmakologie und Toxikologie. 17. Aufl. Stuttgart: Thieme Verlag; 2010
    Google Scholar
  • 2 Balogh A, Haen E. Klinische Pharmakologie in der Zahnärztlichen Praxis. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH; 2010
    Google Scholar
  • 3 Matos P, Jordan P. Beyond Cox-Inhibition: „Side-effects“ of Ibuprofen on Neoplastic Development and progression. Curr Pharmaceutic Design 2015; 21: 2978-2982
    PubMedGoogle Scholar
  • 4 Gurpinar E, Grizzle WE, Piazza GA. NSAIDs inhibit tumorigenesis, but how?. Clin Cancer Res 2014; 20: 1104-1113
    CrossrefPubMedGoogle Scholar
  • 5 Lewis SC, Langman MJ, Laporte JR. et al. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on Individual patient data. Br J Clin Pharmacol 2002; 54: 320-326
    CrossrefPubMedGoogle Scholar
  • 6 Moore N, Vanganse E, Leparc JM. et al. The pain study: Paracetamol, Aspirin and Ibuprofen new tolerability study: a large-scale, randomised clinical trial comparing the tolerability of aspirin, ibuprofen and paracetamol for short-term analgesia. Clin Drug Investig 1999; 18: 89-98
    CrossrefPubMedGoogle Scholar
  • 7 Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclooxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: Population based nested case-control analysys. BMJ 2005; 331: 1310-1316
    CrossrefPubMedGoogle Scholar
  • 8 Xin C, Li-hong W, Yang Y. et al. Ibuprofen ion-Exchange fiber complex: improved dissolution and gastric tolerance based on ion-Exchange. Drug Dev Ind Pharm 2013; 39: 744-751
    CrossrefPubMedGoogle Scholar
  • 9 Fukushima E, Monoi N, Mikoshiba S. et al. Protective effects of acetaminophen on ibuprofen-induced gastric mucosa damage in rats with associated suppression of matrix metalloproteinase. J Pharmacol Exp Ther 2014; 349: 165-173
    CrossrefPubMedGoogle Scholar
  • 10 Moore N, Salvo F, Duong M. et al. Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC. Expert Opin Drug Saf 2014; 13: 167-179
    CrossrefPubMedGoogle Scholar
  • 11 Lipworth L, Friis S, Blot WJ. et al. A population-based cohort study of mortality among users of ibuprofen in Denmark. Am J Ther 2004; 11: 156-163
    CrossrefPubMedGoogle Scholar
  • 12 Griffin MC. Nonsteroidal anti-inflammatory drugs should not be routinely administered for postoperative analgesia after cardiac surgery. J Cardiothorac Vasc Anesth 2000; 14: 735-738
    CrossrefPubMedGoogle Scholar
  • 13 Akinbamowo AO, Salzberg DJ, Weir MR. Renal consequences of prostaglandin inhibition in heart failure. Heart Fail Clin 2008; 4: 505-5102
    CrossrefPubMedGoogle Scholar
  • 14 Weir MR. Renal effects of nonselective NSAIDS and coxibs. Cleve Clin J Med 2002; 69 (Suppl. 01) 153-158
    CrossrefPubMedGoogle Scholar
  • 15 Griffin MR, Yared A, Ray WA. Nonsteroidal anti-inflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000; 151: 488-496
    CrossrefPubMedGoogle Scholar
  • 16 Veltri JC, Rollins DE. A comparison of the frequency and severity of poisoning cases for ingestion of acetaminophen, aspirin and ibuprofen. Am J Emerg Med 1988; 6: 104-107
    CrossrefPubMedGoogle Scholar
  • 17 Moro I, Matozzo V, Piovan A. et al. Morpho-physiological effects of ibuprofen on Scenedesmus rubescens. Environ Toxicol Pharmacol 2014; 38: 379-387
    CrossrefPubMedGoogle Scholar
  • 18 Bagnoli F, Rossetti A, Messina G. et al. Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. J Matern Fetal Neonatal Med 2013; 26: 423-429
    CrossrefPubMedGoogle Scholar
  • 19 Southworth SR, Woodward E, Peng A. et al. An integrated safety analysis of intravenous Ibuprofen (Caldalor) in adults. J Pain Res 2015; 8: 753-765
    PubMedGoogle Scholar
  • 20 Wong T, Stang AS, Ganshorn H. et al. Combined and alternating paracetamol and ibuprofen therapy for febrile children (review). Evid Based child Health: A Cochrane review J 2014; 9: 675-729
    PubMedGoogle Scholar
  • 21 Lapi F, Azoulay L, Yin H. et al. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ 2013; 346: e8525
    CrossrefPubMedGoogle Scholar
  • 22 Pavlicevic I, Glavaski M, Rumboldt M. et al. Prohypertensive effects of non-steroidal anti-inflammatory drugs are mostly due to vasoconstriction. Coll Antropol 2011; 35: 817-822
    PubMedGoogle Scholar
  • 23 Masclee GM, Valkhoff VE, Coloma PM. et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology 2014; 147: 784-792
    CrossrefPubMedGoogle Scholar
  • 24 Gurwitz JH, Everitt DE, Monane M. et al. The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons. J Gerontol A Biol Sci Med Sci 1996; 51: M74-M79
    PubMedGoogle Scholar
  • 25 Catella-Lawson F, Reilly MP, Kapoor SC. et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-1817
    CrossrefPubMedGoogle Scholar
  • 26 Information for Healthcare Professionals: Concomitant use of Ibuprofen and Aspirin. Silver Spring, MD: U.S. Food and Drug Administration; 2006. [Accessed March 21, 2015]
    Google Scholar
  • 27 Kurth T, Glynn RJ, Walker AM. et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal anti-inflammatory drugs. Circulation 2003; 108: 1191-1195
    CrossrefPubMedGoogle Scholar
  • 28 Antonicelli L, Tagliabracci A. Asthma death induced by ibuprofen. Monaldi Arch Chest Dis 1995; 50: 276-278
    PubMedGoogle Scholar
  • 29 Goraya JS, Virdi VS. To the editor: Exacerbation of asthma by ibuprofen in a very young child. Pediatr Pulmonol 2001; 32: 262
    CrossrefPubMedGoogle Scholar
  • 30 Mellemkjaer L, Blot WJ, Sorensen HAT. et al. Upper gastrointestinal bleeding among users of NSAIDs: a population based cohort study in Denmark. Br J Clin Pharmacol 2002; 53: 173-181
    CrossrefPubMedGoogle Scholar
  • 31 Greenblatt DJ, von Moltke LL. Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol 2005; 45: 127-132
    CrossrefPubMedGoogle Scholar
  • 32 Zullino DF, Khazaal Y. Increased risk of gastrointestinal adverse effects under SSRI/NSAID combination may be due to pharmacokinetic interactions. Br J Clin Pharmacol 2005; 59: 118-119
    CrossrefPubMedGoogle Scholar
  • 33 de Jong JC, van den Berg PB, Tobi H. et al. Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. Br J Clin Pharmacol 2003; 55: 591-595
    CrossrefPubMedGoogle Scholar
  • 34 Ragheb M. Ibuprofen can increase serum lithium level in lithium-treated patients. J Clin Psychiatry 1987; 48: 161-163
    PubMedGoogle Scholar
  • 35 Kaufmann DW, Kelly JP, Wiholm BE. et al. The risk of acute major upper gastrointestinal bleeding among users of aspirin and ibuprofen at various levels of alcohol consumption. Am J Gastroenterol 1999; 94: 3189-3196
    CrossrefPubMedGoogle Scholar
  • 36 Haas DA. Adverse drug interactions in dental practice: interactions associated with analgesics. Part III in a series Am Dent Assoc 1999; 130: 397-407
    PubMedGoogle Scholar
  • 37 Oppel P, Brune K. Schmerzmittel in der Zahnheilkunde. Quintessenz 2013; 64: 75-83
    PubMedGoogle Scholar
  • 38 Qazi SM, Sindby EJ, Norgaard MA. Ibuprofen – a safe analgesic during cardiac surgery recovery? A randomized controlled trial. J Cardiovasc Thorac Res 2015; 7: 141-148
    CrossrefPubMedGoogle Scholar
  • 39 Fan H, Zheng Z, Feng W. et al. Risk factors and prevention of upper gastrointestinal hemorrhage after a coronary artery bypass grafting operation. Surg Today 2010; 40: 931-935
    CrossrefPubMedGoogle Scholar
  • 40 Scarpignato C, Lanas A, Blandizzi C. et al. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Medicine 2015; 13: 55-77
    CrossrefPubMedGoogle Scholar